Theravance Biopharma Inc - ROE
TBPH
Price:
$16.9
Market Cap:
$875.90M
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and...[Read more]
Industry
Biotechnology
IPO Date
2014-05-16
Stock Exchange
NASDAQ
Ticker
TBPH
PE Ratio
[-221.78]
ROE
[43.85%]
Current Ratio
[13.14]
Dividend Yield
[0%]
Enterprise Value
[661.10M]
Dividend History
The ROE as of August 2026 (TTM) for Theravance Biopharma Inc (TBPH) is 43.85%
According to Theravance Biopharma Inc’s latest financial reports and current stock price. The company's current ROE is 43.85%. This represents a change of 291.43% compared to the average of 11.20% of the last 4 quarters.
Theravance Biopharma Inc (TBPH) Historical ROE (quarterly & annually)
How has TBPH ROE performed in the past?
The mean historical ROE of Theravance Biopharma Inc over the last ten years is 54.66%. The current 43.85% ROE has changed -19.78% with respect to the historical average. Over the past ten years (40 quarters), TBPH's ROE was at its highest in in the September 2018 quarter at 442.05%. The ROE was at its lowest in in the June 2018 quarter at -118.70%.
Average
54.66%
Median
47.30%
Minimum
-247.79%
Maximum
417.77%
Theravance Biopharma Inc (TBPH) ROE by Quarter and Year
Discovering the peaks and valleys of Theravance Biopharma Inc ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 355.16%
Maximum Annual ROE = 417.77%
Minimum Annual Increase = -268.60%
Minimum Annual ROE = -247.79%
| Year | ROE | Change |
|---|---|---|
| 2025 | 35.69% | -211.04% |
| 2024 | -32.14% | 24.03% |
| 2023 | -25.91% | -113.13% |
| 2022 | 197.40% | 235.14% |
| 2021 | 58.90% | -35.65% |
| 2020 | 91.53% | -13.36% |
| 2019 | 105.64% | -74.71% |
| 2018 | 417.77% | -268.60% |
| 2017 | -247.79% | 355.16% |
| 2016 | -54.44% | -27.38% |
Theravance Biopharma Inc (TBPH) Average ROE
How has TBPH ROE performed in the past?
The current ROE of Theravance Biopharma Inc (TBPH) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-7.45%
5-year avg
46.79%
10-year avg
54.66%
Theravance Biopharma Inc (TBPH) ROE vs. Peers
How is TBPH’s ROE compared to its peers?
Theravance Biopharma Inc’s ROE is less than BlackRock Innovation and Growth Term Trust (0.64%), greater than Monte Rosa Therapeutics, Inc. (-40.99%), greater than Day One Biopharmaceuticals, Inc. (-23.43%), greater than Geron Corporation (-28.90%), greater than Replimune Group, Inc. (-128.57%), greater than Vir Biotechnology, Inc. (-53.31%), greater than LENZ Therapeutics, Inc. (-46.82%), greater than ArriVent BioPharma, Inc. (-48.98%), greater than Valneva SE (-106.22%), greater than Tyra Biosciences, Inc. (-46.39%),
| Company | ROE | Market cap |
|---|---|---|
| 0.64% | $994.37M | |
| -40.99% | $1.31B | |
| -23.43% | $2.22B | |
| -28.90% | $1.04B | |
| -128.57% | $988.15M | |
| -53.31% | $1.53B | |
| -46.82% | $164.30M | |
| -48.98% | $1.43B | |
| -106.22% | $498.77M | |
| -46.39% | $1.54B |
Build a custom stock screener for Theravance Biopharma Inc (TBPH) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Theravance Biopharma Inc using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Theravance Biopharma Inc (TBPH) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Theravance Biopharma Inc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Theravance Biopharma Inc's ROE?
How is the ROE calculated for Theravance Biopharma Inc (TBPH)?
What is the highest ROE for Theravance Biopharma Inc (TBPH)?
What is the 3-year average ROE for Theravance Biopharma Inc (TBPH)?
What is the 5-year average ROE for Theravance Biopharma Inc (TBPH)?
How does the current ROE for Theravance Biopharma Inc (TBPH) compare to its historical average?